Compare CVS Health Corp (CVS) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Marvell Technology Inc — how do they compare? CVS Health Corp trades at $88.05 (market cap $112.29B), while Marvell Technology Inc trades at $275.4 (market cap $246.84B). The key difference: Marvell Technology Inc is far larger — about 2.2× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Marvell Technology Inc for 42 Days on average.
| CVS | MRVL | |
|---|---|---|
Market Cap | $112.29B | $246.84B |
Volume | 7,763,676 | 29,003,830 |
Sector | Health | Technology |
52-Week High | $110.60 | $316.43 |
52-Week Low | $70.08 | $73.73 |
Typical Hold Time | 83 Days | 42 Days |
Enterprise Value | $174.64B | $248.19B |
Dividend Yield | 3.03% | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 expected at $1.1. Revenue growth is accelerating, driven by data center and custom AI chip demand, though current valuations are elevated with a P/E of 90.95. Recent news highlights a major Google deal and raised fiscal 2028 revenue guidance to $18 billion.
The outlook remains positive given robust AI infrastructure spending and management's optimistic forecasts. Key risks include high valuation multiples, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish with a $327.86 price target, suggesting significant upside potential if growth targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
